碱性磷酸酶的新型抑制剂可抑制血管平滑肌细胞钙化。
Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification.
作者信息
Narisawa Sonoko, Harmey Dympna, Yadav Manisha C, O'Neill W Charles, Hoylaerts Marc F, Millán Jose Luis
机构信息
The Burnham Institute, La Jolla, California, USA.
出版信息
J Bone Miner Res. 2007 Nov;22(11):1700-10. doi: 10.1359/jbmr.070714.
UNLABELLED
We report three novel inhibitors of the physiological pyrophosphatase activity of alkaline phosphatase and show that these compounds are capable of reducing calcification in two models of vascular calcification (i.e., they suppress in vitro calcification by cultured Enpp1(-/-) VSMCs and they inhibit the increased pyrophosphatase activity in a rat aortic model).
INTRODUCTION
Genetic ablation of tissue-nonspecific alkaline phosphatase (TNALP) leads to accumulation of the calcification inhibitor inorganic pyrophosphate (PP(i)). TNALP deficiency ameliorates the hypermineralization phenotype in Enpp1(-/-) and ank/ank mice, two models of osteoarthritis and soft tissue calcification. We surmised that the pharmacological inhibition of TNALP pyrophosphatase activity could be used to prevent/suppress vascular calcification.
MATERIALS AND METHODS
Comprehensive chemical libraries were screened to identify novel drug-like compounds that could inhibit TNALP pyrophosphatase function at physiological pH. We used these novel compounds to block calcification by cultured vascular smooth muscle cells (VSMCs) and to inhibit the upregulated pyrophosphatase activity in a rat aortic calcification model.
RESULTS
Using VSMC cultures, we determined that Enpp1(-/-) and ank/ank VSMCs express higher TNALP levels and enhanced in vitro calcification compared with wildtype cells. By high-throughput screening, three novel compounds, 5,361,418, 5,923,412, and 5,804,079, were identified that inhibit TNALP pyrophosphatase function through an uncompetitive mechanism, with high affinity and specificity when measured at both pH 9.8 and 7.5. These compounds were shown to reduce the calcification by Enpp1(-/-) VSMCs. Furthermore, using an ex vivo rat whole aorta PP(i) hydrolysis assay, we showed that pyrophosphatase activity was inhibited by all three lead compounds, with compound 5,804,079 being the most potent at pH 7.5.
CONCLUSIONS
We conclude that TNALP is a druggable target for the treatment and/or prevention of ectopic calcification. The lead compounds identified in this study will serve as scaffolds for medicinal chemistry efforts to develop drugs for the treatment of soft tissue calcification.
未标注
我们报告了三种新型碱性磷酸酶生理焦磷酸酶活性抑制剂,并表明这些化合物能够在两种血管钙化模型中减少钙化(即它们抑制培养的Enpp1(-/-)血管平滑肌细胞的体外钙化,并抑制大鼠主动脉模型中增加的焦磷酸酶活性)。
引言
组织非特异性碱性磷酸酶(TNALP)的基因敲除导致钙化抑制剂无机焦磷酸(PP(i))的积累。TNALP缺乏改善了Enpp1(-/-)和ank/ank小鼠的高矿化表型,这是两种骨关节炎和软组织钙化模型。我们推测,TNALP焦磷酸酶活性的药理抑制可用于预防/抑制血管钙化。
材料与方法
筛选综合化学文库,以鉴定在生理pH值下可抑制TNALP焦磷酸酶功能的新型类药物化合物。我们使用这些新型化合物来阻断培养的血管平滑肌细胞(VSMC)的钙化,并抑制大鼠主动脉钙化模型中上调的焦磷酸酶活性。
结果
使用VSMC培养物,我们确定Enpp1(-/-)和ank/ank VSMC与野生型细胞相比表达更高的TNALP水平并增强了体外钙化。通过高通量筛选,鉴定出三种新型化合物5,361,418、5,923,412和5,804,079,它们通过非竞争性机制抑制TNALP焦磷酸酶功能,在pH 9.8和7.5测量时具有高亲和力和特异性。这些化合物显示可减少Enpp1(-/-) VSMC中的钙化。此外,使用离体大鼠全主动脉PP(i)水解试验,我们表明所有三种先导化合物均抑制焦磷酸酶活性,化合物5,804,079在pH 7.5时最有效。
结论
我们得出结论,TNALP是治疗和/或预防异位钙化的可药物作用靶点。本研究中鉴定的先导化合物将作为药物化学研究的支架,以开发用于治疗软组织钙化的药物。